ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its participation in the following conferences in September 2023. Details of the conferences and management presentation are as follows:
H.C. Wainwright 25th Annual Global Investment Conference (Hybrid)
Presentation: Monday, September 11th at 11:30 a.m. E.S.T
Presenter: Mr. Raj Kannan, CEO
One-on-one and small group meetings: Sept 11-13, 2023
Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; Dr. Andrew Zhu, President and Head of R&D; and Mr. Tyler Ehler, Senior Director, Investor Relations
For more information, please contact your H.C. Wainwright representative.
2023 Cantor Global Healthcare Conference (In Person)
Presentation: Thursday, September 28th at 2:25 p.m. E.S.T.
Presenter: Mr. Raj Kannan, CEO; and Dr. John Hayslip, CMO
One-on-one and small group meetings: Sept 26-28, 2023
Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; and Mr. Tyler Ehler, Senior Director, Investor Relations
For more information, please contact your Cantor representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.
I-Mab Contacts
Investors | Media |
Tyler Ehler | Gigi Feng |
Senior Director, Investor Relations | Chief Communications Officer |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$4.38 |
| Daily Change: | 0.22 5.17 |
| Daily Volume: | 975,067 |
| Market Cap: | US$357.260M |
July 17, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
